Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Intra-Cellular Therapies, Inc. ITCI NASDAQ

NASDAQ Global Select • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
55/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$132.00
+0.1%

Intra-Cellular Therapies, Inc. (ITCI) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $131.87. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is ITCI = $132 (+0.1% upside).

Financials: revenue is $681M, +112.6%/yr average growth. Net income is $75M (loss), growing at +33.9%/yr. Net profit margin is -11% (negative). Gross margin is 91.6% (+1.4 pp trend).

Balance sheet: total debt is $17M against $1.1B equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 6.36 (strong liquidity). Debt-to-assets is 1.2%. Total assets: $1.4B.

Analyst outlook: 14 / 23 analysts rate ITCI as buy (61%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 50/100 (Partial), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 72/100 (Pass), Future 55/100 (Partial), Income 10/100 (Fail).

$132.00
▲ 0.1% Upside
Average Price Target
The 12-month price target for Intra-Cellular Therapies, Inc. is $132.00.

ITCI SharesGrow Score Overview

65/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 50/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 72/100
Gross margin is + market cap
FUTURE 55/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ITCI

~
VALUE Partial
50/100
ITCI trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $132, implying +0.1% from the current price $132. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
ITCI: +112.6%/yr revenue is, +33.9%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ITCI: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 6.36 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✓
MOAT Pass
72/100
ITCI: Gross margin is 91.6% (+1.4 pp trend), $14B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 72/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
55/100
Analyst outlook: 14 / 23 analysts rate ITCI as buy (61%). Analyst consensus target is $132 (+0.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ITCI: Net profit margin is -11%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range64.09-131.98
Volume16.04M
Avg Volume (30D)3.62M
Market Cap$14.05B
Beta (1Y)0.46
Share Statistics
EPS (TTM)-0.72
Shares Outstanding$103.13M
IPO Date2014-01-07
Employees860
CEOSharon Mates
Financial Highlights & Ratios
Revenue (TTM)$680.85M
Gross Profit$623.89M
EBITDA$-116.72M
Net Income$-74.68M
Operating Income$-116.72M
Total Cash$1B
Total Debt$16.98M
Net Debt$-289.97M
Total Assets$1.37B
Price / Earnings (P/E)-183.2
Price / Sales (P/S)20.63
Analyst Forecast
1Y Price Target$132.00
Target High$132.00
Target Low$132.00
Upside+0.1%
Rating ConsensusBuy
Analysts Covering23
Buy 61% Hold 39% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS46116X1019

Price Chart

Track all markets on TradingView
ITCI
Intra-Cellular Therapies, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Drug Manufacturers - Specialty & Generic
64.09 52WK RANGE 131.98

People Also View

NBIX
NBIX
Neurocrine Biosciences, Inc.
$130.81
+3.55%
 ALKS
ALKS
Alkermes plc
$33.87
+0.36%
 AMRX
AMRX
Amneal Pharmaceuticals, Inc.
$13.12
+2.26%
 DCPH
DCPH
Deciphera Pharmaceuticals, Inc.
$25.59
+0.08%
 DVAX
DVAX
Dynavax Technologies Corporation
$15.50
+0.00%
 ANIP
ANIP
ANI Pharmaceuticals, Inc.
$78.29
-0.03%
 COLL
COLL
Collegium Pharmaceutical, Inc.
$35.64
+0.06%
 PCRX
PCRX
Pacira BioSciences, Inc.
$23.75
-1.29%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message